BioNTech SE (BNTX)
| Market Cap | 18.72B |
| Revenue (ttm) | 2.97B |
| Net Income (ttm) | 122.83M |
| Shares Out | 237.73M |
| EPS (ttm) | 0.51 |
| PE Ratio | 157.66 |
| Forward PE | 7.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 493,767 |
| Open | 78.79 |
| Previous Close | 78.83 |
| Day's Range | 78.02 - 79.23 |
| 52-Week Range | 78.02 - 125.83 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 112.82 (+43.25%) |
| Earnings Date | Aug 5, 2024 |
About BNTX
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinic... [Read more]
Financial Performance
In 2023, BioNTech SE's revenue was 3.82 billion, a decrease of -77.94% compared to the previous year's 17.31 billion. Earnings were 930.30 million, a decrease of -90.14%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for BNTX stock is "Buy." The 12-month stock price forecast is $112.82, which is an increase of 43.25% from the latest price.
News
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) ...
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
MAINZ, Germany and SHANGHAI, China, June 24, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today announced that the U.S. Food and Drug Adminis...
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
BioNTech SE's BNTX partner MediLink Therapeutics (Suzhou) Co., Ltd says the FDA has placed a partial clinical hold on the Phase 1 trial.
US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug
Germany's BioNTech SE said in a regulatory filing on Monday the U.S. Food and Drug Administration has placed a partial clinical hold on an early-stage study of its experimental cancer drug.
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
COPENHAGEN, Denmark & MAINZ, Germany--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX) today announced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluating ...
New U.S. bird-flu case is first with respiratory symptoms, CDC says
A new human bird-flu case identified in a Michigan dairy worker is the first in the U.S. to involve acute respiratory symptoms, the Centers for Disease Control and Prevention said Thursday.
BioNTech wins up to $145 mln in CEPI support for African mRNA vaccine plants
COVID-19 vaccine maker BioNTech won up to $145 million in funding from a global coalition against infectious diseases to build a production network in African countries for messenger-RNA based shots.
BioNTech and CEPI Expand Partnership to Strengthen Africa's mRNA Vaccine Ecosystem
MAINZ, Germany/OSLO, Norway, May 29, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) and the Coalition for Epidemic Preparedness Innovations (“CEPI”) are expanding their strategic partner...
MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership
SUZHOU, China, May 26, 2024 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces a new strategic collaboration with BioNTech SE (Nas...
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company's diversified immuno-oncology pipeline at...
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated T...
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) held its Annual General Meeting (“AGM”) today, May 17, 2024. A total of 87.51 per cent of the sh...
BioNTech's Outlook Gives Vaccine Maker a Shot in the Arm
American depositary receipts (ADRs) of BioNTech (BNTX) were down less than 1% in intraday trading Monday after the COVID-19 vaccine maker shrugged off losses and tumbling sales in the first quarter, g...
BioNTech Revenue Falls Sharply on Reduced Covid Vaccine Sales
The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.
BioNTech says 90% of 2024 revenues will accrue at end of year
Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the...
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low chemotherapy-...
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-1...
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Addit...
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
MAINZ, Germany, April 7, 2024 - BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neoantigen-sp...
BioNTech gets US agency notice over default on COVID vaccine royalties
BioNTech said on Monday the U.S. National Institutes of Health has sent a notice to the German company regarding default on the payment of royalties and other amounts related to its COVID-19 vaccine.
BioNTech Earnings Fall Short of Estimates. The Stock Is Down.
The pharmaceutical firm has been hit hard as demand for Covid-19 vaccines plunged.
BioNTech Q4 earnings: COVID franchise to remain a notable cash contributor in 2024
BioNTech SE (NASDAQ: BNTX) is down nearly 5.0% in premarket on Wednesday after reporting disappointing financial results for the fourth quarter. BioNTech stock down on muted guidance The stock is bein...
BioNTech's stock sinks after earnings fall below expectations, hurt by writedowns of vaccine inventory
Shares of BioNTech SE BNTX, +1.22% dropped 4.4% in premarket trading Wednesday, after the Germany-based biotechnology company reported fourth-quarter results that fell sharply to miss expectations, we...
After earnings plunge, BioNTech pins hopes on cancer drug launches
Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, reported on Wednesday a plunge in 2023 revenue and earnings as its focus shifts towards canc...
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024 Aiming for first oncology launch in 2026 and ten ...